SE9904121D0 - Hydrophobe biomolecular structure - Google Patents

Hydrophobe biomolecular structure

Info

Publication number
SE9904121D0
SE9904121D0 SE9904121A SE9904121A SE9904121D0 SE 9904121 D0 SE9904121 D0 SE 9904121D0 SE 9904121 A SE9904121 A SE 9904121A SE 9904121 A SE9904121 A SE 9904121A SE 9904121 D0 SE9904121 D0 SE 9904121D0
Authority
SE
Sweden
Prior art keywords
hydrophobic
biomolecular structure
biomolecular
new
hydrophobe
Prior art date
Application number
SE9904121A
Other languages
English (en)
Swedish (sv)
Inventor
Gustaf Jederstroem
Original Assignee
Gustaf Jederstroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gustaf Jederstroem filed Critical Gustaf Jederstroem
Priority to SE9904121A priority Critical patent/SE9904121D0/xx
Publication of SE9904121D0 publication Critical patent/SE9904121D0/xx
Priority to US09/455,472 priority patent/US6448093B1/en
Priority to DE60017783T priority patent/DE60017783T2/de
Priority to CA002391647A priority patent/CA2391647C/en
Priority to EP00980185A priority patent/EP1231926B1/en
Priority to PCT/SE2000/002245 priority patent/WO2001036656A2/en
Priority to AT00980185T priority patent/ATE287720T1/de
Priority to AU17481/01A priority patent/AU1748101A/en
Priority to ES00980185T priority patent/ES2236004T3/es
Priority to US10/186,732 priority patent/US6926910B2/en
Priority to US11/179,673 priority patent/US7338931B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9904121A 1999-11-15 1999-11-15 Hydrophobe biomolecular structure SE9904121D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9904121A SE9904121D0 (sv) 1999-11-15 1999-11-15 Hydrophobe biomolecular structure
US09/455,472 US6448093B1 (en) 1999-11-15 1999-12-06 Hydrophobe biomolecular structure
ES00980185T ES2236004T3 (es) 1999-11-15 2000-11-15 Complejo biomolecular formado entre el acido hialuronico y una biomolecula, su procedimiento de produccion y su utilizacion medica.
EP00980185A EP1231926B1 (en) 1999-11-15 2000-11-15 Biomolecular complex formed between hyaluronic acid and a biomolecule, its method of manufacture and medical uses thereof
CA002391647A CA2391647C (en) 1999-11-15 2000-11-15 Biomolecular complex formed between hyaluronic acid and a biomolecule
DE60017783T DE60017783T2 (de) 1999-11-15 2000-11-15 Biomolekularer komplex,gebildet aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung
PCT/SE2000/002245 WO2001036656A2 (en) 1999-11-15 2000-11-15 A complex between hyaluronic acid and a biomolecule and its use
AT00980185T ATE287720T1 (de) 1999-11-15 2000-11-15 Biomolekularer komplex gebilded aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung
AU17481/01A AU1748101A (en) 1999-11-15 2000-11-15 New complex, and methods for its production and use
US10/186,732 US6926910B2 (en) 1999-11-15 2002-07-02 Hydrophobe biomolecular structure
US11/179,673 US7338931B2 (en) 1999-11-15 2005-07-13 Hydrophobic biomolecular structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904121A SE9904121D0 (sv) 1999-11-15 1999-11-15 Hydrophobe biomolecular structure

Publications (1)

Publication Number Publication Date
SE9904121D0 true SE9904121D0 (sv) 1999-11-15

Family

ID=20417718

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904121A SE9904121D0 (sv) 1999-11-15 1999-11-15 Hydrophobe biomolecular structure

Country Status (9)

Country Link
US (3) US6448093B1 (xx)
EP (1) EP1231926B1 (xx)
AT (1) ATE287720T1 (xx)
AU (1) AU1748101A (xx)
CA (1) CA2391647C (xx)
DE (1) DE60017783T2 (xx)
ES (1) ES2236004T3 (xx)
SE (1) SE9904121D0 (xx)
WO (1) WO2001036656A2 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4790911B2 (ja) 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US7144870B2 (en) * 2002-02-15 2006-12-05 Research Development Foundation Hyaluronic acid mediated adenoviral transduction
JP4851185B2 (ja) 2003-05-16 2012-01-11 ジェレックスインターナショナル株式会社 アレルギー症状抑制剤及び空気濾過フィルター
AU2006274509B2 (en) 2005-07-27 2012-01-19 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
ATE516050T1 (de) * 2007-05-07 2011-07-15 Jederstrom Pharmaceuticals Ab Stabilisierte suspension
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
SE7901565L (sv) 1979-02-21 1980-08-22 Pharmacia Ab Medel for immunisering
DE2907070A1 (de) * 1979-02-23 1980-09-04 Hoechst Ag Heterocyclische spiroverknuepfte amidine und verfahren zu ihrer herstellung
NO169637C (no) * 1983-10-11 1992-07-22 Fidia Spa Fremgangsmaate for fremstilling av terapeutisk aktive hyaluronsyre-fraksjoner
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
US5637566A (en) * 1988-08-24 1997-06-10 Southern Cross Biotech Pty. Ltd. Method of improving carcass quality by administering growth hormone
SE8804164A0 (sv) 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
ATE173405T1 (de) 1991-07-10 1998-12-15 Takeda Chemical Industries Ltd Arzneimittel auf basis von hyaluronsäure
US5614212A (en) * 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5654006A (en) * 1993-02-12 1997-08-05 Mayo Foundation For Medical Education And Research Condensed-phase microparticle composition and method
AU1552995A (en) * 1993-12-17 1995-07-03 Spinal Cord Society Method for inducing dna synthesis in neurons
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
DE69618938T2 (de) * 1995-03-28 2002-10-31 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
CA2235685A1 (en) 1995-10-23 1997-05-01 Hyal Pharmaceutical Australia Limited Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
WO1997037680A1 (en) * 1996-04-05 1997-10-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
JPH10158196A (ja) * 1996-05-16 1998-06-16 Hisamitsu Pharmaceut Co Inc 核酸安定化用キャリアー
EP0986404B1 (en) * 1996-07-10 2002-04-17 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Gene therapy delivery system for targeting to endothelia
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure

Also Published As

Publication number Publication date
EP1231926A2 (en) 2002-08-21
WO2001036656B1 (en) 2002-02-28
DE60017783T2 (de) 2006-01-05
US6926910B2 (en) 2005-08-09
US20070275069A9 (en) 2007-11-29
DE60017783D1 (de) 2005-03-03
US7338931B2 (en) 2008-03-04
US6448093B1 (en) 2002-09-10
WO2001036656A3 (en) 2001-11-15
CA2391647C (en) 2008-03-11
WO2001036656A2 (en) 2001-05-25
ATE287720T1 (de) 2005-02-15
AU1748101A (en) 2001-05-30
CA2391647A1 (en) 2001-05-25
EP1231926B1 (en) 2005-01-26
ES2236004T3 (es) 2005-07-16
US20050255162A1 (en) 2005-11-17
US20030096266A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
ATE334662T1 (de) Herstellungsverfahren von arzneizubereitungen
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
CL2008002673A1 (es) Procedimiento se preparacion de citalopram que comprende hacer reaccionar un compuesto derivado de benzofurano con un agente eshidratante y una sulfonamida (div. sol. 2003-01).
ATE443501T1 (de) Tamponeinführhülse
UY27381A1 (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
DE60002918D1 (de) Herstellung von betonbeschleuniger
NO20011272L (no) Fremgangsmåte for fremstilling av ren citalopram
NO20011271A (no) Fremgangsmåte for fremstilling av ren citalopram
SE9904121D0 (sv) Hydrophobe biomolecular structure
EA200301223A1 (ru) Лекарственные формы окскарбазепина
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
DE50105771D1 (de) Ibuprofen-wirkstoffzubereitung
ZA200308353B (en) Compaction process for manufacture of sodium phenytoin dosage form.
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
EA200200728A1 (ru) Способ получения циталопрама
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
ATE307598T1 (de) Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen
BR0012622A (pt) Derivados de 3-amino-2-benzil-1-fenil-propano
DE60214154D1 (de) Pharmazeutisches freigabekonstrukt zur magenretention
BR0106120A (pt) Processo para produção de isolongifolanol
BR0016781A (pt) Bases de 1-naftol e 2-naftol - mannich substituìdas